June 2026
Proprietary AI analyst is now available
Largest Medical Imaging & Diagnostics Public Companies
Benchmark revenue and EBITDA valuation multiples for public comps like
Agilent, Natera, GE HealthCare, Quest Diagnostics and Labcorp.
 | Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations. | $138 | +17% | $39B | $41B | 5.8x | 20.3x | ||
| Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. | $222 | +31% | $32B | $31B | 13.4x | (140.4x) | ||
| GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company’s sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%). | $64 | -14% | $29B | $37B | 1.8x | 9.9x | ||
| Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions. | $196 | +9% | $22B | $28B | 2.5x | 12.7x | ||
| Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing. | $261 | -1% | $21B | $28B | 2.0x | 11.6x | ||
| Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. | $104 | +95% | $20B | $21B | - | - | ||
| Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. | $133 | +156% | $18B | $18B | 18.6x | (82.2x) | ||
 | Shanghai United Imaging Healthcare Co Ltd provides customers with high-performance medical imaging equipment, radiotherapy products, life science instruments, and medical digitalization and intelligent solutions. The company’s products include MRI systems, CT scanners, X-ray imaging equipment, molecular imaging systems, radiotherapy linear accelerators, and life science instruments. | $16 | -11% | $14B | $13B | 6.1x | 33.3x | ||
 | Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe. | $114 | -44% | $12B | $12B | 77.1x | 99.6x | ||
| Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China. | $102 | +6% | $11B | $14B | 4.9x | 16.4x | ||
 | BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France. | $82 | -39% | $10B | $10B | 2.0x | 8.1x | ||
| Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%). | $38 | -26% | $8B | $9B | 4.2x | 11.5x | ||
| Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 35% of group revenue in Australia and New Zealand, 25% in the US, and 40% in Europe. | $14 | -29% | $7B | $11B | 1.5x | 8.8x | ||
| Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc. | $103 | +26% | $7B | $7B | 4.4x | 11.9x | ||
| RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. | $53 | -7% | $4B | $6B | 2.8x | 17.9x | ||
| Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies. | $50 | +85% | $4B | $4B | 6.9x | 25.2x | ||
 | Diasorin develops and manufactures a broad portfolio of in vitro diagnostics used for detecting pathogens and contamination of samples from the human body, as well as used in industrial settings such as food and water contamination testing. The company operates three segments: immunodiagnostics (66% of sales), molecular diagnostics (17%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment’s importance has decreased over the years, and in 2024, it accounted for only 2% of total sales. | $78 | -26% | $4B | $5B | 3.3x | 10.0x | ||
| Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer. | $9 | -47% | $3B | $3B | 4.3x | 79.2x | ||
| GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service. | $67 | +29% | $3B | $2B | 14.2x | (5.5x) | ||
 | Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India. | $16 | +7% | $3B | $3B | 10.1x | 31.5x | ||
| HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States. | $29 | -- | $2B | $2B | 13.4x | (71.0x) | ||
 | Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world. | $3 | -30% | $2B | $2B | 3.6x | 13.5x | ||
 | Fleury SA is engaged in the provision of medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics and ophthalmology areas and offers its digital healthcare platform. The company carries out its activities through customer service units and hospital-based units. Furthermore, the company has a mobile service operation with coverage in municipalities in addition to a digital platform. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from Diagnostic Medicine Segment. | $3 | +15% | $2B | $2B | 1.4x | 4.7x | ||
 | Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online. | $46 | +1% | $2B | $2B | 2.8x | 11.2x | ||
| NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. | $11 | +55% | $1B | $2B | 2.4x | 40.0x | ||
| Ramsay Generale de Sante SA operates in the private healthcare sector in France. The company provides a comprehensive range of patient care services in thirteen business segments: Nouvelle Aquitaine, Bourgogne-Franche Comte, Brittany, Centre-Val de Loire, Hauts de France, Normandy, Provence Alpes Cote d'Azur, Ile de France, Auvergne-Rhone Alpes, Occitanie, Italy, Nordics, and Head Office. It generates maximum revenue from the Ile de France segment. The company also specializes in cardiology, heart surgery, digestive surgery, dermatology, urology, ophthalmology, vascular and endovascular surgery. | $13 | +2% | $1B | $6B | 1.0x | 8.4x | ||
| Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional’s pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. The company enables the practical application of ultrasound information in the clinical workflow. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. With its small, handheld size, low cost, and simple user interface. | $5 | +160% | $1B | $1B | 12.7x | (46.7x) | ||
| Daan Gene Co Ltd is a high-tech enterprise-oriented in molecular diagnostic techniques. It is primarily committed to research and development, production, and service of in-vitro diagnostic products, including qPCR, Sequeacing, TRF, ELISA, and Liquid-Based Cytology diagnostic kits and equipment. Geographically, tahe group operates in China. | $1 | +3% | $1B | $1B | 10.1x | (16.9x) | ||
| Beijing Wandong Medical Technology Co Ltd is engaged in the development, manufacture, and distribution of medical equipment. Its products consist of radiological imaging equipment, including angiographic and cardiac systems, digital direct radiography (DR) imaging equipment, high frequency diagnostic systems, high frequency radiographic systems, conventional x-ray diagnostic equipment and high frequency mobile units, magnetic resonance imaging (MRI) equipment, as well as digital medical image management systems, among others. The company is also engaged in providing maintenance services. | $2 | -28% | $1B | $838M | 4.2x | (22.3x) | ||
| Sinocare Inc operates in the healthcare industry. It is engaged in the development, manufacturing, and marketing of diagnosis testing products for people with chronic diseases and healthcare professionals. Its product range covers household blood glucose meter, medical blood glucose meter, urinary microalbumin test strip and blood lipid uric acid products. In addition, the company also provides diabetes management information systems. | $2 | -33% | $1B | $1B | 1.8x | 21.4x | ||
| Sonoscape Medical Corp is a Chinese manufacturer of medical devices for ultrasound diagnostic systems and transducers. The company's product categories include Ultrasound, Endoscope which also includes video equipment, and Electrocardiography consisting of veterinary ECG and resting ECG. Ultrasound category covers color Doppler trolley systems, color Doppler HCU, B/W trolley systems, and probe, among others. The organization has a business presence in China and in other countries. | $3 | -33% | $1B | $1B | 3.1x | 26.3x | ||
| Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production, and sales of POCT in vitro diagnostic products. | $8 | +88% | $1B | $875M | 14.0x | 31.8x | ||
| Guangzhou Wondfo Biotech Co Ltd manufactures medical diagnostic tests. Its products include immunodiagnostic rapid test kits, including fertility, which include pregnancy HCG, ovulation LH, and others. The company's products are used in a clinical test, field test, and personal health management, among others. | $2 | -23% | $1B | $910M | 3.0x | 34.2x | ||
 | Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain. | $67 | +41% | $1B | $1B | 3.1x | 10.8x | ||
| RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops advanced software solutions for improved cancer treatment. The company develops and markets the RayStation* treatment planning system and RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of Sweden, North America, Asia Pacific, Europe and the rest of the world. | $24 | -34% | $822M | $815M | 5.4x | 12.4x | ||
| Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities including MRIs, CT scans, PET scans, X-rays, ultrasounds, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated from the Outpatient segment, which generates revenue by performing imaging studies and providing radiologists’ interpretations of those studies. | $8 | -- | $792M | $2B | 1.7x | 7.4x | ||
 | Lunit Inc is a medical AI software company devoted to providing AI-powered total cancer care. Its products comprise of Lunit INSIGHT CXR, AI solution for Chest x-ray; Lunit INSIGHT MMG, AI solution for Mammography; Lunit SCOPE IO, AI-Powered Biomarker for Immuno-Oncology; and Lunit SCOPE PD-L1, AI Solution for PD-L1 Expression. | $10 | -74% | $741M | $811M | 14.8x | (114.7x) | ||
| Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications. | $30 | +42% | $669M | $767M | 2.9x | 14.8x | ||
| Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia). | $1 | +108% | $657M | $2B | 0.9x | 4.7x | ||
| Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets. | $22 | +6% | $655M | $430M | 1.2x | 10.0x | ||
| Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series. | $7 | -1% | $612M | $439M | 8.8x | 90.4x | ||
| Assure Tech (Hangzhou) Co Ltd is a biotechnology company. The company is engaged in research & development, production, sell of diagnostic reagents, POCT and biological materials. | $5 | -14% | $606M | $347M | 5.2x | 19.0x | ||
| Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia. | $1 | -20% | $540M | $945M | 2.1x | 12.1x | ||
| Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific. | $10 | +21% | $441M | $728M | 0.9x | 6.2x | ||
 | NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world. | $1 | -10% | $345M | $319M | 4.9x | 14.3x | ||
| Voxel SA is a network of diagnostic imaging laboratories created for patients and to increase access to high-quality tests. The company operates diagnostic imaging centers and laboratories and provides several services such as magnetic resonance imaging, computed tomography and positron emission tomography. It has 33 specialised laboratories in 21 cities throughout Poland. | $31 | -29% | $326M | $375M | 2.3x | 7.2x | ||
| Australian Clinical Labs is Australia’s third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory. | $1 | -26% | $273M | $481M | 0.9x | 3.6x | ||
| Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. | $3 | +10% | $248M | $532M | 2.8x | 19.6x | ||
| Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. | $1 | -17% | $194M | $203M | 43.1x | (3.6x) | ||
 | Curasight AS is a clinical-stage biotech company committed to improving both the diagnosis and the treatment of certain types of cancer. The company is focused on generating data with both uTRACE and uTREAT in cancers, including prostate cancer and glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non small cell lung cancer (NSCLC), and pancreatic cancer. | $4 | +973% | $180M | $176M | - | (20.7x) | ||
| Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. | $16 | +192% | $171M | $217M | 2.4x | (12.4x) | ||
| Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. | $10 | -26% | $171M | $168M | 6.0x | 57.3x | ||
| Healius is Australia’s second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex. | $0 | -59% | $166M | $800M | 0.8x | 5.2x | ||
 | Detection Technology PLC is a company engaged in providing X-ray imaging subsystems, components and services for medical, security and industrial applications. The business units of the company are the Medical business unit and Security and Industrial business unit, of which prime revenue is derived from the Security Business Unit. Its security imaging offering includes X-ray imaging subsystems for security applications from baggage, parcel and cargo scanning to personnel screening and computed tomography. The company operates in Finland, APAC, Other EMEA and Americas. | $10 | -19% | $153M | $129M | 1.1x | 9.9x | ||
| EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements. | $0 | -1% | $153M | $136M | 2.0x | 8.0x | ||
| Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software. | $2 | +108% | $149M | $121M | 9.0x | (3.4x) | ||
| Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services. | $2 | -60% | $144M | $92M | 7.1x | (1.9x) | ||
| Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue principally from the provision of AI-based software solutions, sales of hardware devices, and other services. Geographically, the company generates the majority of its revenue from Mainland China. | $1 | -14% | $143M | $51M | 2.0x | (52.6x) | ||
| Bioneer Corp engages in the manufacture and sale of biotechnological products in South Korea. It offers deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits, DNA and ribonucleic acid (RNA) amplification products, human diagnostics kits, veterinary diagnostics kits, among others. | $5 | -44% | $140M | $149M | 0.7x | 9.7x | ||
| Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue. | $19 | +28% | $120M | $105M | - | - | ||
| Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. | $5 | -31% | $116M | $120M | 1.8x | (12.2x) | ||
| Infinitt Healthcare Co Ltd is a Korea-based company engaged in developing digital solutions used in hospitals. The company offers clinical solutions, enterprise imaging solutions and radiology solutions. The solutions offered by the company are enterprise imaging, radiology, cardiology, pathology, dental imaging, and other cloud solutions. | $5 | +4% | $114M | ($10M) | (0.2x) | (0.4x) | ||
| Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services. | $34 | -17% | $107M | $69M | 2537.6x | (5.8x) | ||
| Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. | $0 | -7% | $100M | $92M | 14.7x | (7.1x) | ||
| Allianca Saude e Participacoes SA formerly Centro de Imagem Diagnosticos SA - Alliar is a diagnostic imaging company consisting of MRI machines, CT scanners and ultrasound machines. Its products include diagnostic medicine, diagnostic imaging and clinical analysis. The company is also engaged in the import of medical and hospital equipment, diagnosis kits, and related goods; Providing health consulting, advisory, courses and lectures. | $1 | -36% | $94M | $201M | 0.8x | 5.5x | ||
| Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK. | $18,459 | -- | $93M | $69M | 1.4x | 9.1x | ||
| TeraView Holdings PLC is a holding company. It provides specialized solutions for semiconductor packaging, automotive painting and high-value-added coating, and lithium-ion batteries, leveraging non-destructive testing and measurement technology utilizing terahertz (THz) frequencies. The company offers customized solutions for each industry based on its accumulated technological prowess and is expanding into various markets. Its product offerings include EOTPR, TeraCota 3000, TeraCota 3500, and TeraPulse. The maximum revenue is being generated from EOTPR (Electro-Optical Terahertz Pulse Reflectometry), which is a solution for non-destructively diagnosing various defects occurring in the semiconductor packaging process. | $2 | -- | $82M | $82M | - | - | ||
| FluoGuide AS is a clinical-stage biotechnology company focused on developing drugs that maximize surgical outcomes by making cancer fluorescent. Its technology includes uPAR, which is part of a proteolytic system, and FG001, a product injected into the patient's vein prior to surgery. | $5 | +14% | $81M | $76M | - | (12.2x) | ||
 | Agfa-Gevaert NV develops, produces, and distributes a range of analog and digital imaging systems and information technology solutions, for the printing sector, healthcare sector, and specific industrial applications. The company's operating segment includes CONOPS; Digital Print and Chemicals; Radiology Solutions and Healthcare IT. It generates maximum revenue from the Digital Print and Chemicals segment. The company operates in Europe, NAFTA, Latin America and Asia/Oceania/Africa. | $1 | -58% | $78M | $208M | 0.2x | 3.1x | ||
| Vuno Inc is engaged in the business of manufacturing medical devices and equipment. The company develops and markets bone age testing equipment, brain quantification medical device, X-ray reading aid solutions, imaging devices, and other related devices. | $5 | -62% | $77M | $58M | 2.5x | (23.9x) | ||
| Aiforia Technologies PLC equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services plan to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. | $2 | -44% | $71M | $68M | 16.7x | (9.8x) | ||
| Klea Holding focused on the acquisition, development and digitalization of companies in multiple sectors. Its development of Smart Salem, the first network of digital medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the Emirates United Arabs, or its Smart Health joint venture developed in Saudi Arabia. | $0 | +8% | $68M | $70M | 3.5x | 15.4x | ||
| Chandan Healthcare Ltd operates laboratories that offer comprehensive pathological investigations. Its services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, it provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. The company operates single reportable business segment that is Diagnostics Services. | $2 | +23% | $61M | $66M | 2.8x | 14.8x | ||
 | Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America. | $4 | -41% | $60M | $52M | 2.8x | 13.8x | ||
| INIFY Laboratories AB provides cancer diagnostics through ultra-modern laboratory services within pathology. It uses a fully digital, standardized, and AI-supported workflow to optimize quality and response times, initially within the prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. | $1 | -19% | $58M | $56M | 24.0x | (8.4x) | ||
| Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment. | $0 | -31% | $57M | $57M | 2.5x | (5.0x) | ||
| Mach7 Technologies Ltd is a healthcare software company focused on enterprise imaging infrastructure. The company’s vendor neutral platform enables health systems to manage, access, and exchange medical imaging data across departments, sites, and vendors. It serves across North America, Asia-Pacific, and the Middle East, with deployments ranging from academic medical centres to multi-site health networks. A substantial part of revenue is derived in the form of Subscription revenue. Geographically, it derives a majority of its revenue from North America. | $0 | -3% | $54M | $41M | 2.5x | (35.4x) | ||
| HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company’s ability to develop higher-resolution ECG solutions is achieved through the development of the Company’s proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products. | $1 | -27% | $50M | $48M | - | (2.3x) | ||
 | MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe. | $27 | -5% | $49M | $45M | 2.4x | 11.3x | ||
| Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment. | $1 | +1% | $41M | $30M | 1.1x | (2.8x) | ||
| Deepnoid Inc is a doctor-driven medical AI platform. It is an open platform that supports doctor-led medical imaging AI model research efficiently. It uses both the image processing module and neural network module provided by default for free, and can effectively use computing resources in the form of a cloud. | $2 | -59% | $39M | $31M | 6.4x | (5.0x) | ||
| MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe. | $1 | -73% | $31M | $94M | 0.9x | (72.0x) | ||
| ContextVision AB is a medical technology company. It develops and sells image enhancement software for medical diagnosis and artificial intelligence. Its product portfolio includes image enhancement software for 2D/3D/4D (dimensional) ultrasound, magnetic resonance imaging (MRI), X-Ray, radiography, and mammography. its geographical segments are Asia, Europe, and America. | $0 | -25% | $28M | $22M | 1.7x | 9.1x | ||
| NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use. | $2 | +23% | $26M | $18M | 3.3x | (4.5x) | ||
| Micro-X Ltd operates in the medical industry. The company is engaged in the design, development, manufacturing, and commercialisation of imaging products for the healthcare and security markets utilising Micro-X’s proprietary cold cathode X-ray technology. Its products include Head CT, Rover, Argus, Checkpoints, and Baggage CT Scanner imaging devices. In addition, the group also offers custom imaging solutions based on the specific requirements of its customers. Its geographical operating segments are the United States, which generates maximum revenue, and Australia. | $0 | -- | $20M | $19M | 2.0x | (2.4x) | ||
| Biosynex SA is engaged in the research, development, and manufacturing of fast diagnosis tests on membrane support for health professionals. It manufactures and markets medical devices for screening, diagnosis. | $1 | -24% | $20M | $81M | 0.7x | 58.6x | ||
 | EBM Technologies Inc is engaged in picture archiving and communication systems. Its products include EBM diagnostic and reviewing station, EBM storage and utility server, and EBM breast imaging for PACS. The company develops and markets medical information technology solutions; and provides to the health sector. | $1 | -17% | $20M | $18M | 2.2x | 19.4x | ||
 | Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada. | $0 | +17% | $19M | $18M | 242.6x | (7.1x) | ||
| SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe. | $1 | +1% | $19M | $17M | 2.7x | (18.7x) | ||
| CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company’s CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform. | $0 | -36% | $17M | $26M | 3.0x | (3.6x) | ||
| Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. | $0 | -39% | $14M | $8M | 73.7x | (0.9x) | ||
| Predilife SA develops solutions for predictive medicine, combining medical techniques (genetic tests, medical imaging) and mathematical models with a large amount of statistical data, which allows each individual to define their risk profile for the occurrence of various serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States. | $3 | -25% | $12M | $17M | 24.2x | (3.8x) | ||
| BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog. | $3 | -29% | $12M | $16M | 1.1x | 12.5x | ||
| Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes. | $7 | +0% | $9M | $8M | 0.9x | 5.7x | ||
| Synthetic MR AB develops software solutions for Magnetic Resonance Imaging that support shorter exam times and deliver more information to the clinician. Its product is available in different packages. SyMRI IMAGE provides high MRI workflows and enables automatic segmentation of brain tissue, providing objective decision support, MAGiC is a customer-specific version of SyMRI IMAGE marketed and sold by GE Healthcare under a license agreement, SyMRI NEURO includes contrast images, biomarker segmentation, volumetric measurements of brain tissues and quantitative parametric maps, and SyMRI Research Edition includes contrast images, volumetric measurements and quantitative maps to provide more information to the researcher. | $0 | -75% | $8M | $4M | 0.7x | (1.4x) | ||
| Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. | $0 | -16% | $5M | $4M | 2.1x | (6.1x) | ||
| Brainscan SA is an AI system for lesion detection in the human brain based on computed tomography images. Algorithms powered by artificial intelligence analyze CT brain scans, automatically detecting and highlighting potential pathological changes. | $4 | -48% | $5M | $5M | 40.1x | (6.2x) | ||
| Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making, and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. Its operating segments include Medical Imaging and Feedback Medical Imaging India. Its products include Bleepa, a regulated communication platform for sharing clinical results and supporting multidisciplinary teamwork, and CareLocker, a patient-facing platform that provides access and control over diagnostic and clinical data. | $0 | -- | $5M | ($603K) | (0.5x) | 0.1x | ||
| Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments. | $0 | +11% | $3M | $3M | - | (2.7x) | ||
| Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector. | $0 | -57% | $3M | $2M | 38.0x | (0.6x) | ||
| Median | $4 | -14% | $176M | $213M | 2.8x | 6.2x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.